Dose–exposure–efficacy response of intravenous immunoglobulin G 10% in multifocal motor neuropathy
Annals of Clinical and Translational Neurology · 2024
DOI: 10.1002/acn3.52098 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Annals of Clinical and Translational Neurology, 2024. Verfasst von Zhaoyang Li und 3 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology & Early Clinical Development, Takeda Development Center Americas, Inc., Cambridge, Massachusetts, USA. Hauptthemen laut MEDLINE: Immunoglobulins, Intravenous, Hand Strength, Cross-Over Studies. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Takeda Development Center Americas, Inc.
Abstract (Originalsprache)
Objective
Multifocal motor neuropathy is a rare chronic immune‐mediated neuropathy with impaired grip strength representing a common symptom. While intravenous immunoglobulin G is an effective treatment for the disease, significant variation in treatment response has been observed but not well understood. This analysis characterized dose–exposure–response relationships in multifocal motor neuropathy, using grip strength as a clinical efficacy measure.
Methods
Serum immunoglobulin G trough concentrations and grip strength data for the more affected hand from a Phase 3, randomized, double‐blind, placebo‐controlled, crossover trial of intravenous immunoglobulin 10% in 44 patients with multifocal motor neuropathy (NCT00666263) were used to develop a population pharmacokinetic–pharmacodynamic model.
Results
The model adequately described the observed pharmacokinetic and pharmacodynamic data and relationships between intravenous immunoglobulin 10% dose, serum immunoglobulin G trough levels, grip strength, and inter‐patient variabilities in multifocal motor neuropathy. Model‐based simulations for various dosing regimens (0.4–2.0 g/kg every 2–4 weeks) indicated that ≥1.6 g/kg/month would achieve clinically meaningful improvements in grip strength (≥4 kg) in ≥70% of patients. More frequent dosing at an equivalent monthly dose led to a more consistent response in grip strength. Furthermore, splitting the dose over multiple days for high doses (>1 g/kg) did not impact grip strength.
Interpretation
These findings suggest that the majority of patients with multifocal motor neuropathy would respond rapidly to intravenous immunoglobulin 10% with a range of dosing regimens. Shorter dosing intervals may avoid the diminishing response seen with longer dosing intervals. Dose‐splitting provided similar outcomes while offering flexibility and convenience.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Clinical Pharmacology & Early Clinical Development, Takeda Development Center Americas, Inc., Cambridge, Massachusetts, USA.
- Pharmacometrics, Cognigen, a division of Simulations Plus, Buffalo, New York, USA.
- Quantitative Clinical Pharmacology, Cognigen, a division of Simulations Plus, Buffalo, New York, USA.
- Clinical Medicine, Takeda Development Center Americas, Inc., Cambridge, Massachusetts, USA.
ORCID-Profile: Zhaoyang Li, Ryan Franke, Leman Yel
Förderung
- Takeda Development Center Americas, Inc
Zitieren
APA
Li, Z., Roepcke, S., Franke, R., & Yel, L. (2024). Dose–exposure–efficacy response of intravenous immunoglobulin G 10% in multifocal motor neuropathy. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.52098
Vancouver
Li Z, Roepcke S, Franke R, Yel L. Dose–exposure–efficacy response of intravenous immunoglobulin G 10% in multifocal motor neuropathy. Annals of Clinical and Translational Neurology. 2024. doi:10.1002/acn3.52098
BibTeX
@article{Li2024,
author = {Li, Zhaoyang and Roepcke, Stefan and Franke, Ryan and Yel, Leman},
title = {Dose–exposure–efficacy response of intravenous immunoglobulin G 10% in multifocal motor neuropathy},
journal = {Annals of Clinical and Translational Neurology},
year = {2024},
doi = {10.1002/acn3.52098}
}
EUVIMED